Composition for preventing or treating keloids or hypertrophic scars

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

What is claimed is: 
     
         1 . A pharmaceutical composition for preventing or treating keloids or hypertrophic scars comprising, as an active ingredient, a material that inhibits the activity of one or more proteins selected from the group consisting of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 or inhibits the expression of genes encoding the one or more proteins. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the active ingredient comprises shRNA, siRNA, miRNA, an antisense oligonucleotide, a ribozyme, Crispr/Cas9, a DNAzyme, a peptide nucleic acid (PNA), a peptide, an antibody, an aptamer, a natural extract, or a chemical. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the active ingredient comprises shRNA, siRNA, miRNA, or an antisense oligonucleotide, which inhibits the expression of the genes. 
     
     
         4 . A method of screening a material for preventing or treating keloids or hypertrophic scar, comprising:
 (a) treating tissues derived from a patient with keloids or hypertrophic scars with a test material; and   (b) analyzing the activity of one or more proteins selected from the group consisting of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 or analyzing an expression level of genes encoding the proteins in the tissues or cells treated with the test material,   wherein the test material is judged to be a material for preventing or treating keloids or hypertrophic scars when the activity of the proteins or the expression pattern of the genes encoding the proteins in the tissues or cells treated with the test material is different from that in normal tissues.   
     
     
         5 . A composition for diagnosing keloids or hypertrophic scars, comprising a material used to measure an expression level of one or more genes selected from the group consisting of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5, or an expression level of one or more proteins selected from the group consisting of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5. 
     
     
         6 . A method of diagnosing keloids or hypertrophic scars, comprising:
 measuring an expression level of one or more genes selected from the group consisting of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 or an expression level of one or more proteins selected from the group consisting of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 in a sample obtained from a subject having or expecting to have a keloid or hypertrophic scar; and   comparing the results of measurement with the expression levels of the genes or proteins in the sample from the normal subject.   
     
     
         7 . A method of treating a subject having a keloid or hypertrophic scar, comprising:
 (a) administering a pharmaceutical composition, which comprises, as an active ingredient, a material that inhibits the expression of one or more genes selected from the group consisting of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 or inhibits the activity of one or more proteins selected from the group consisting of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5, to the subject having a keloid or hypertrophic scar.